 Non-dilutive funding strengthens balance sheet and extends current operating runway into 2025The sale of an additional 1.8 million of unused New Jersey NOLs expected in 2023 LAWRENCEVILLE, NJ, Jan. 12, 2023 GLOBE NEWSWIRE IMUNON, Inc. NASDAQ: IMNN, a clinical-stage drug development company today announced it has received 1.6 million in net cash proceeds from the sale of... The post IMUNON Receives 1.6 Million from Sale of its New Jersey Net Operating Losses appeared first on DKODING... 